RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53 R249S Mutation and is a Potential Therapeutic Target
Authors:
Open Access
- 8 September 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 12 (48) , e00335
Abstract
TP53 mutations are highly associated with hepatocellular carcinoma (HCC), a common and deadly cancer. However, few primary drivers in the progression of HCC with mutant TP53 have been identified. To uncover tumor suppressors in human HCC, a genome‐wide CRISPR/Cas9‐based screening of primary human hepatocytes with MYC and TP53 R249S overexpression (MT‐PHHs) is performed in xenografts. The screen identified RELA as one of the most significant genes, besides NF2 and CSK , two known tumor suppressor genes (TSG) in HCC. Ablation of RELA increased the expression of genes related to cell cycling and stemness in MT‐PHHs, and induced PHHs to transform into HCC in situ in Fah‐deficient immunodeficient mice. Additionally, loss of RELA facilitated HCC metastasis via Epithelial‐Mesenchymal Transition (EMT). Clinically, low RELA expression is positively associated with poor prognosis and large tumor size in HCC patients. In terms of its underlying mechanism, reduced RELA expression promoted DVL1 expression, thereby enhancing β‐catenin nuclear translocation, and thus strengthening Wnt/β‐catenin signaling. Excitingly, betulinic acid (BetA), a RELA agonist, increased RELA activation and suppressed both growth and metastasis of hepatoma cells with TP53 R249S overexpression in xenografts. This study reveals RELA as a tumor suppressor in HCC with TP53 R249S overexpression, offering a potential therapeutic target.Keywords
Funding Information
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2023371)
- Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515110349)
- Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515012484)
- Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515012569)
- Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515012360)
- Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515010604)
- Basic and Applied Basic Research Foundation of Guangdong Province (2024B1515040020)
- Basic and Applied Basic Research Foundation of Guangdong Province (2020B1212060052)
- Science and Technology Planning Project of Guangdong Province (2024A0505040021)
- Science and Technology Planning Project of Guangdong Province (2023B1212060050)
- Science and Technology Planning Project of Guangdong Province (2023B1212120009)
- National Natural Science Foundation of China (82202031)
- National Natural Science Foundation of China (32370996)
- National Natural Science Foundation of China (82273377)
- National Natural Science Foundation of China (82402150)
- National Natural Science Foundation of China (32170946)
- National Natural Science Foundation of China (82341204)
- Key Technologies Research and Development Program (2022YFE0210600)
This publication has 74 references indexed in Scilit:
- EIF4A3‐Mediated Biogenesis of CircFADS1 Promotes the Progression of Hepatocellular Carcinoma via Wnt/β‐Catenin PathwayAdvanced Science, 2025
- Wnt/β-catenin signaling inhibits oxidative stress-induced ferroptosis to improve interstitial cystitis/bladder pain syndrome by reducing NF-κBBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2024
- Targeting cell-cycle machinery in cancerCancer Cell, 2021
- Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative PhosphorylationCancer Cell, 2019
- Loss of PDK4 switches the hepatic NF‐κB/TNF pathway from pro‐survival to pro‐apoptosisHepatology, 2018
- Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2017
- The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapyCancer Letters, 2009
- NF-κB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapyCancer Letters, 2009
- Reduced C–Terminal Src Kinase (Csk) Activities in Hepatocellular CarcinomaHepatology, 1999
- p53 mutation in hepatocellular carcinoma after aflatoxin exposureThe Lancet, 1991